Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $36.70

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given an average rating of “Moderate Buy” by the eleven research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $36.70.

Several brokerages have recently commented on VRDN. HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. The Goldman Sachs Group reduced their target price on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Viridian Therapeutics in a report on Tuesday. JMP Securities reduced their target price on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. Finally, Royal Bank of Canada reduced their target price on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th.

Viridian Therapeutics Trading Up 7.8%

Shares of Viridian Therapeutics stock opened at $13.82 on Friday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -3.21 and a beta of 0.57. The business has a fifty day simple moving average of $13.29 and a 200-day simple moving average of $17.01. Viridian Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. On average, equities analysts forecast that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Viridian Therapeutics

Institutional investors have recently modified their holdings of the stock. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics during the 4th quarter valued at $26,000. Amalgamated Bank boosted its stake in shares of Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after buying an additional 840 shares during the period. Foresite Capital Management VI LLC acquired a new stake in shares of Viridian Therapeutics during the 4th quarter valued at $38,000. AlphaQuest LLC boosted its stake in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Viridian Therapeutics by 3,892.9% during the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock valued at $114,000 after buying an additional 8,214 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.